Concerns Emerge Over Weight Loss and Diabetes Injections
Recent data from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) indicates that weight loss and diabetes injections, used by over a million people, might be linked to serious side effects, including some fatalities.
This group of drugs, which includes Mounjaro, Wegovy, and Ozempic, has shown potential associations with pancreas inflammation. The MHRA has reported 181 cases of either acute or chronic pancreatitis connected to Mounjaro, with five fatalities attributed to it. Meanwhile, Wegovy and Ozempic have been linked to 113 pancreatitis cases and one death.
Other variations of these GLP-1 medications have also been implicated in similar reports. However, it’s important to note that there is currently no direct evidence linking these drugs to the reported deaths, and the MHRA has not deemed it necessary to restrict access to them.
It’s interesting to consider that pancreatitis can occur in individuals who aren’t taking GLP-1 medications, with an estimated 560 cases per million people in the general population, often due to factors like gallstones or alcohol consumption.
To better understand the risks, the MHRA and Genomics England are initiating a study aimed at uncovering possible genetic factors that may make certain individuals more susceptible to pancreatitis when using these drugs. People who reported pancreatitis through the MHRA’s alert system will be invited to provide saliva samples for genetic testing.
Professor Matt Brown, chief scientific officer at Genomics England, mentioned that while GLP-1 medications have gained significant attention, they also carry risks of serious side effects, similar to any medication. He expressed optimism about the potential for personalized treatment approaches that could minimize adverse reactions, many of which may have genetic origins.
The symptoms of pancreatitis typically include severe abdominal pain, fever, and nausea. Acute cases often require hospitalization for treatment, and while most recover in a few days, complications can arise, leading to a fatality rate of around 5% in these cases.
As with all medications, there’s a risk-benefit balance to consider. For individuals battling type 2 diabetes or obesity, the benefits of these injections can be substantial—they help in lowering blood sugar levels, facilitate rapid weight loss, and can reduce the risk of cardiovascular disease by up to 20%.
However, those who are slightly overweight and have sought these injections privately for minor weight loss may not see the same health benefits. This situation serves as a real wake-up call for such individuals.
These are potent medications influencing not only appetite but also functioning of various organs, including the brain. Pancreatitis represents just one of numerous potential side effects associated with these treatments.
Lilly, the manufacturer of Mounjaro, emphasized that patient safety remains their highest priority. Their information leaflet mentions that acute pancreatitis is an uncommon side effect, affecting possibly 1 in 100 individuals. Furthermore, they recommend that patients consult their doctor if they have a history of pancreatitis prior to using Mounjaro.
